Citrine Pharmaceutical

Citrine Medicine is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative therapies for rare diseases, specifically for the Chinese market. The company utilizes a strategic licensing model, partnering with global biotechnology firms to bring late-stage assets to Greater China to address significant unmet medical needs. Its lead programs include maralixibat for Alagille syndrome and arimoclomol for Niemann-Pick disease type C. Headquartered in Shanghai with offices in the United States, Citrine is backed by a syndicate of premier life science investors including Vivo Capital and F-Prime Capital.